
Oncologists discuss data from the NETTER-1 and NETTER-2 trials and the extent to which they support the applicability of 177Lu-dotatate in NETs.

Your AI-Trained Oncology Knowledge Connection!


Oncologists discuss data from the NETTER-1 and NETTER-2 trials and the extent to which they support the applicability of 177Lu-dotatate in NETs.

Given that well-differentiated grade 3 NETs are relatively new, standard-of-care treatment options are undefined.

Published: November 12th 2024 | Updated: